Sharon Lynch, MD
Neurology · Kansas City, KSNPI 1730288143
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $897 of the $1,077 with a category attached, or 83.3%. 13 manufacturers reported payments, led by Bristol Myers Squibb at 35.6% of the total.
Across 57 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$383
- AstraZeneca$181
- Amgen$98
- Vanda Pharmaceuticals Inc.$82
- Biogen$78
- TG Therapeutics, Inc.$54
- plus $201 from 7 others
Across 592 payments — averaging $15,705 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5.5M
- Genentech, Inc.$1.2M
- Sanofi$537K
- F. Hoffmann-la Roche AG$442K
- Bristol Myers Squibb$305K
- TG Therapeutics, Inc.$288K
- plus $1.1M from 12 others
What the payments were for
- Speaking & faculty fees$15014%
- Food & beverage$89783%
- Education$303%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 28 | $383 |
| AstraZeneca | 3 | $181 |
| Amgen(2 entities) | 5 | $98 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| Biogen | 5 | $78 |
| TG Therapeutics, Inc. | 2 | $54 |
| Sanofi | 2 | $44 |
| AbbVie(2 entities) | 2 | $36 |
| Banner Life Sciences, LLC | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Invivyd Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| CSL Behring | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIRIS$150
How this compares
$1,077 in reported general payments places this provider in the 55th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnspryngSatralizumab-Mwge | 54 | $947,383 |
| Kesimpta PenOfatumumab | 92 | $807,564 |
| AubagioTeriflunomide | 87 | $770,343 |
| CopaxoneGlatiramer Acetate | 99 | $543,005 |
| GilenyaFingolimod Hcl | 28 | $282,472 |
| RebifInterferon Beta-1a/Albumin | 26 | $262,775 |
| MayzentSiponimod | 26 | $243,477 |
| FingolimodFingolimod Hcl | 118 | $202,714 |
| Avonex (4 Pack)Interferon Beta-1a | 25 | $202,073 |
| BetaseronInterferon Beta-1b | 21 | $192,598 |
| Glatiramer Acetate | 59 | $139,723 |
| VumerityDiroximel Fumarate | 13 | $111,858 |
| GlatopaGlatiramer Acetate | 51 | $107,048 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $93,984 |
| Dalfampridine ErDalfampridine | 386 | $60,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $44 | $770,34387 claims |
| BiogenAvonex (4 Pack), Vumerity | $78 | $313,93138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 131 neurology providers in Kansas.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.